6 results about "Angiogenesis inhibitor" patented technology

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39 / ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.

The present disclosure relates to methods of treating cancer, such as lung cancer (e.g., non-small cell lung cancer) by administering a dry powder to the respiratory tract of a subject in need thereof (e.g., by oral inhalation), the dry powder comprising respirable dry particles that comprise an angiogenesis inhibitor (e.g., itraconazole), and optionally a stabilizer (e.g., polysorbate 80) and / or one or more excipients (e.g., leucine and a sodium salt, such as sodium sulfate).

Described herein are compositions for modulating transgene expression of one or more therapeutic agents. In some aspects, an engineered polynucleotide comprises one or more expression cassettes, the one or more expression cassettes encoding a first angiogenesis inhibitor and a second angiogenesis inhibitor. Also described herein are methods of using the compositions described herein for modulating transgene expression and for treating diseases or conditions, in particular therapeutic agents for treating ocular diseases or inhibiting neovascularization.

Providing pharmaceutical compositions for the treatment of melanoma. [Solution] A pharmaceutical composition comprising (a) an LXRβ agonist selected from the following compounds 1, 2, 12, and 25, and / or a salt thereof, and (b) an antiproliferative compound selected from immunomodulators, topoisomerase inhibitors, antimetabolites, angiogenesis inhibitors, tyrosine kinase inhibitors, alkylating agents, and mitotic inhibitors. TIFF2026062949000078.tif110166

The present invention relates to an antibody fragment specifically binding to vascular endothelial growth factor (VEGF) and, more specifically, to a dimeric antibody fragment comprising a structure in which two antibody fragments are dimerized by a SARAH domain, and expressing high binding affinity and excellent biological activity for VEGF. The antibody of the present invention inhibits VEGF-induced proliferation of human vascular endothelial cells (HUVEC) and blocks VEGFR2-mediated signaling, and thus effectively inhibits angiogenesis.

The invention relates to the field of medicine, namely to ophthalmology, and can be used in the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks. The technical objective is to develop an effective method for the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks, by performing simultaneous transpupillary laser coagulation of the retina only in the nasal quadrants and introducing an angiogenesis inhibitor into the vitreous cavity. The proposed method solves this problem, involving simultaneous transpupillary laser photocoagulation of avascular zones of the retina in the nasal quadrants only and the injection of an angiogenesis inhibitor into the vitreous cavity. This method prevents the development of tractional retinal detachment, which causes blindness and low vision in children, reactivation of active ROP, and postoperative uveitis, which require additional surgical treatment, in 100% of cases.